Holm-Jorgensen Rasmus 4
4 · Acrivon Therapeutics, Inc. · Filed Nov 16, 2022
Insider Transaction Report
Form 4
Holm-Jorgensen Rasmus
Chief Financial Officer
Transactions
- Award
Common Stock
2022-11-14+20,030→ 20,030 total - Award
Stock Option (Right to Buy)
2022-11-14+60,090→ 60,090 totalExercise: $12.50Exp: 2032-11-13→ Common Stock (60,090 underlying)
Footnotes (2)
- [F1]These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
- [F2]Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.